Citation only
via Europe PMC
From NAD<sup>+</sup> elevation to clinical benefit: Tissue-specific regulation and translational barriers in aging and age-related disease.
Pei Z, Zhong M, Jiang Q, Yang A, Wang X, Liang F, Li H.
Pharmacological research · 2026
Abstract
Nicotinamide adenine dinucleotide (NAD<sup>+</sup>) decline has been implicated in aging and age-related disease, and precursor supplementation with nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN) has shown efficacy in preclinical models. Human trials, however, have produced inconsistent functional outcomes, and the sources of this translational gap remain poorly defined. We combined a bibliometric analysis of 3271 aging-focused NAD<sup>+</sup> publications (2004-2025) with a critical synthesis of mechanistic and clinical evidence to localize where and why preclinical findings fail to translate. The bibliometric analysis revealed three structural features of the literature: (i) original research articles dominated the corpus, whereas the document-type classification cannot distinguish preclinical experiments from human observational or interventional studies; (ii) research is siloed across disease domains with limited cross-tissue comparison; and (iii) intervention-oriented keywords (NMN, NR, supplementation, drug delivery) have outpaced empirical clinical validation. Mechanistic synthesis showed that these structural gaps correspond to biological heterogeneity: NAD<sup>+</sup> biosynthesis, consumption, redox balance, and subcellular compartmentalization are tissue- and compartment-specific, such that systemic precursor elevation does not uniformly restore functional NAD<sup>+</sup> in disease-relevant tissues. Four subcellular pools-nuclear, cytosolic, mitochondrial, and axonal-each possess distinct rate-limiting bottlenecks, and hepatic metabolic reserve introduces an overlooked source of inter-individual variability. Across neurodegeneration, metabolic disease, cardiovascular aging, and sarcopenia, NAD<sup>+</sup> dysregulation follows disease-specific mechanisms rather than a universal decline phenotype. We propose a precision-medicine framework that shifts the core question from whether NAD<sup>+</sup> can be elevated to whether a defined intervention corrects a specific NAD<sup>+</sup> defect in the appropriate tissue and subcellular compartment. This framework provides a structured basis for designing next-generation NAD<sup>+</sup>-targeted trials with tissue-specific biomarkers and function-oriented endpoints.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- Europe PMC
- DOI
- 10.1016/j.phrs.2026.109743
- Canonical
- link ↗
- Fetched
- 2026-11-11 MST
Cite this
APA
Z, P., M, Z., Q, J., A, Y., X, W., F, L., & H., L. (2026). From NAD<sup>+</sup> elevation to clinical benefit: Tissue-specific regulation and translational barriers in aging and age-related disease. <em>Pharmacological research</em>. https://doi.org/10.1016/j.phrs.2026.109743
Vancouver
Z P, M Z, Q J, A Y, X W, F L, et al. From NAD<sup>+</sup> elevation to clinical benefit: Tissue-specific regulation and translational barriers in aging and age-related disease. Pharmacological research. 2026. doi:10.1016/j.phrs.2026.109743.
BibTeX
@article{pei2026FromNA,
title = {From NAD<sup>+</sup> elevation to clinical benefit: Tissue-specific regulation and translational barriers in aging and age-related disease.},
author = {Pei Z and Zhong M and Jiang Q and Yang A and Wang X and Liang F and Li H.},
journal = {Pharmacological research},
year = {2026},
doi = {10.1016/j.phrs.2026.109743},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Pharmacological Research 2026
Open access · CC-BY
From NAD+ elevation to clinical benefit: Tissue-specific regulation and translational barriers in aging and age-related disease
Journal of Molecular Endocrinology 2018
Open access · CC-BY
The emergence of the nicotinamide riboside kinases in the regulation of NAD+ metabolism
Metabolites 2026
Open access · OA
Targeting NAD Homeostasis: Compartmentalization, Quantification, and Modulation.
Cells 2022
Open access · CC-BY
NAD+ Metabolism and Interventions in Premature Renal Aging and Chronic Kidney Disease
The European journal of neuroscience 2026
Citation only
Mitochondria-Associated Membranes as a Convergent Hub of Brain Aging: From Neurodegeneration to Cerebral Ischemia.
Annals of Clinical and Medical Case Reports 2025
Open access · OA